In one of the first real-world studies, Tirzepatide shows impressive weight loss results for people without diabetes—shedding nearly 13% of body weight in just six months. Study: Real-world use ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

1 This denial keeps in place the FDA’s declaratory order determining that the shortage of diabetes and weight-loss tirzepatide products has been resolved and phases out compounded tirzepatide ...

The appeal is the latest move in the compounders’ battle to continue making copies of tirzepatide and other GLP-1s, including semaglutide. The FDA declared an end to the 2-year-old tirzepatide ...

By removing both semaglutide and tirzepatide (the actives in Wegovy and Zepbound, respectively) from its drug shortage list, the agency is cutting off the primary legal route that allows ...

Hollie Adams/Reuters In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide ...

The drug builds on the success of earlier treatments such as GLP-1 receptor agonists such as liraglutide and semaglutide and the dual GIP/GLP-1 agonist tirzepatide. Preclinical studies suggested that ...

(Image Credits: Pexel) A new study has revealed that off-label use of semaglutide (Ozempic) and tirzepatide (Mounjaro) leads to significant reductions in HbA1c levels and body weight among adults ...

METAIRIE, La. (WVUE) - A federal judge’s decision last week to restrict compounding pharmacies from producing tirzepatide, the generic version of Eli Lilly’s weight loss drug Zepbound ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...